BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26918824)

  • 1. Inhibiting the Jumonji family: a potential new clinical approach to targeting aberrant epigenetic mechanisms.
    Martinez ED; Gazdar AF
    Epigenomics; 2016 Mar; 8(3):313-6. PubMed ID: 26918824
    [No Abstract]   [Full Text] [Related]  

  • 2. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting histone lysine demethylases by truncating the histone 3 tail to obtain selective substrate-based inhibitors.
    Lohse B; Nielsen AL; Kristensen JB; Helgstrand C; Cloos PA; Olsen L; Gajhede M; Clausen RP; Kristensen JL
    Angew Chem Int Ed Engl; 2011 Sep; 50(39):9100-3. PubMed ID: 21919140
    [No Abstract]   [Full Text] [Related]  

  • 4. Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1.
    Thaler F; Mercurio C
    Expert Opin Ther Pat; 2016 Dec; 26(12):1367-1370. PubMed ID: 27730846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.
    Luo X; Liu Y; Kubicek S; Myllyharju J; Tumber A; Ng S; Che KH; Podoll J; Heightman TD; Oppermann U; Schreiber SL; Wang X
    J Am Chem Soc; 2011 Jun; 133(24):9451-6. PubMed ID: 21585201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural definitions of Jumonji family demethylase selectivity.
    Pilka ES; James T; Lisztwan JH
    Drug Discov Today; 2015 Jun; 20(6):743-9. PubMed ID: 25555749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.
    Liu K; Liu Y; Lau JL; Min J
    Pharmacol Ther; 2015 Jul; 151():121-40. PubMed ID: 25857453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine demethylases inhibitors.
    Suzuki T; Miyata N
    J Med Chem; 2011 Dec; 54(24):8236-50. PubMed ID: 21955276
    [No Abstract]   [Full Text] [Related]  

  • 11. Enabling lead discovery for histone lysine demethylases by high-throughput RapidFire mass spectrometry.
    Hutchinson SE; Leveridge MV; Heathcote ML; Francis P; Williams L; Gee M; Munoz-Muriedas J; Leavens B; Shillings A; Jones E; Homes P; Baddeley S; Chung CW; Bridges A; Argyrou A
    J Biomol Screen; 2012 Jan; 17(1):39-48. PubMed ID: 21859681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new horizon for epigenetic medicine?
    Chen S; Shi Y
    Cell Res; 2013 Mar; 23(3):326-8. PubMed ID: 22986503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
    Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
    J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Jumonji demethylases reprograms severe dilated cardiomyopathy and prolongs survival.
    Tran TA; Zhang QJ; Wang L; Gonzales C; Girard L; May H; Gillette T; Liu ZP; Martinez ED
    J Biol Chem; 2022 Feb; 298(2):101515. PubMed ID: 34933013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
    Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
    Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.
    Yu V; Fisch T; Long AM; Tang J; Lee JH; Hierl M; Chen H; Yakowec P; Schwandner R; Emkey R
    J Biomol Screen; 2012 Jan; 17(1):27-38. PubMed ID: 21859682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
    Kristensen JB; Nielsen AL; Jørgensen L; Kristensen LH; Helgstrand C; Juknaite L; Kristensen JL; Kastrup JS; Clausen RP; Olsen L; Gajhede M
    FEBS Lett; 2011 Jun; 585(12):1951-6. PubMed ID: 21575637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
    Li CY; Wang W; Leung CH; Yang GJ; Chen J
    Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic gene regulation by plant Jumonji group of histone demethylase.
    Chen X; Hu Y; Zhou DX
    Biochim Biophys Acta; 2011 Aug; 1809(8):421-6. PubMed ID: 21419882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.